What are the Historical Developments and Current Growth Metrics of the Remicade Biosimilar Market?
The remicade biosimilar market has seen considerable growth due to a variety of factors.
•The scale of the remicade biosimilar market has substantially increased in the past few years. It is projected to expand from a market size of $3.95 billion in 2024 to $4.93 billion in 2025, with a compound annual growth rate (CAGR) estimated at 24.9%.
Several factors have contributed to the historical growth of this market, including the launch of remicade (infliximab), advancements in biotechnology, the expiration of biologics patents, the establishment of regulatory pathway, and the increasing pressures on healthcare costs.
What Does Future Hold for The Remicade Biosimilar Market Size?
The remicade biosimilar market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for Remicade biosimilars is predicted to skyrocket in the near future, expanding to a value of $11.07 billion in 2029 with a CAGR of 22.4%.
The anticipated rise over the forecast period can be accredited to factors such as expirations of patents, the growing need for economically efficient treatments, the development of the biosimilar pipeline, reimbursement-guiding policies, and market consolidation. Key trends expected during this period encapsulate prescribing habits of physicians, the management of biosimilar lifecycles, naming conventions for biosimilars, the interchangeability of biosimilars, and the real-world implications of biosimilars.
What Key Factors and Trends are Driving the Growth of the Remicade Biosimilar Market?
The escalation in the occurrence of autoimmune diseases, where the immune system inadvertently damages the body's tissues and organs, is projected to drive the expansion of the remicade biosimilar market. Remicade biosimilars offer an effective treatment choice for autoimmune diseases by managing symptoms and reducing associated inflammation. For example, Public Health Scotland reported in July 2023 that the number of newly diagnosed multiple sclerosis (MS) patients in 2022 rose to 87.2%, a surge from 85.7% in 2020. There were 491 fresh cases, raising the total count to 6,359 in 2022. Hence, the increased occurrence of autoimmune diseases is fuelling the growth of the remicade biosimilar market.
What are the Market Segments in the Remicade Biosimilar Market?
The remicade biosimilar market covered in this report is segmented –
1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases
Subsegments:
1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes
2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes
Pre-Book The Remicade Biosimilar Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Remicade Biosimilar Market?
Product innovation stands as a principal trend in the Remicade biosimilar market, with key players designing innovative solutions to solidify their market presence. For example, US biotech firm Amgen Inc., unveiled Amjevita in January 2023, a biosimilar rendition of AbbVie's Humira, in the US market. The launch aimed to replicate the original drug's safety and efficacy. Amjevita, the premier biosimilar of Humira, is looked upon as a possible competitor for Humira in terms of market stake. This biological medication treats numerous autoimmune disorders such as rheumatoid arthritis and Crohn's disease and is among the world's priciest drugs, generating a significant annual revenue for AbbVie. However, Amjevita is anticipated to be substantially more affordable, presenting potential savings and additional treatment alternatives for patients.
Who Are the Key Players in the Remicade Biosimilar Market?
Major companies operating in the remicade biosimilar market include:
• Novartis AG
• Amgen Inc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Merck And Co. Inc.
• LG Chem Ltd.
• Nippon Kayaku Co. Ltd.
• Celltrion Inc.
• Nichi-iko Pharmaceutical Co. Ltd.
• Biocon Limited
• Alvotech S.A.
• MabPharm Ltd.
• Genor Biopharma Co. Ltd
• Shanghai Biomabs Pharmaceuticals Co. Ltd.
• Samsung Bioepis Co. Ltd.
• Biocad Biopharmaceutical Co
• EPIRUS Biopharmaceuticals Inc.
• Ranbaxy Laboratories Limited
• BioXpress Therapeutics SA
• Mabion S.A
What are the Regional Insights into the Remicade Biosimilar Market?
Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
